Squarepoint’s Avadel Pharmaceuticals AVDL Stock Holding History

Squarepoint’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,000	Closed	-$315K	–	4563
2024 Q4	$315K	Buy	+30,000	New	+$364K	﹤0.01%	4112

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Squarepoint's AVDL Position: Q1 2026 in Review

Squarepoint sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 420,072 shares — an estimated $9.05M sold.

Squarepoint first reported a position in AVDL in Q3 2020 and held it in 11 quarters. The position peaked at $9.05M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Squarepoint reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 420,072 Avadel Pharmaceuticals shares in Q1 2026, an estimated $9.05M.
Squarepoint first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 11 quarters.
Squarepoint's Avadel Pharmaceuticals position peaked at $9.05M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.